Forte Biosciences, Inc. (FBRX)
76.99
0.00 (0.00%)
USD |
NASDAQ |
Oct 09, 16:00
Forte Biosciences Free Cash Flow (Quarterly) : -22.70M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -22.70M |
| March 31, 2026 | -18.81M |
| December 31, 2025 | -16.47M |
| September 30, 2025 | -14.06M |
| June 30, 2025 | -10.06M |
| March 31, 2025 | -10.42M |
| December 31, 2024 | -10.04M |
| September 30, 2024 | -8.133M |
| June 30, 2024 | -5.936M |
| March 31, 2024 | -6.673M |
| December 31, 2023 | -8.986M |
| September 30, 2023 | -9.129M |
| June 30, 2023 | -5.475M |
| March 31, 2023 | -5.204M |
| December 31, 2022 | -2.893M |
| September 30, 2022 | -1.94M |
| June 30, 2022 | -1.377M |
| March 31, 2022 | -1.975M |
| December 31, 2021 | -3.582M |
| September 30, 2021 | -5.127M |
| Date | Value |
|---|---|
| June 30, 2021 | -3.938M |
| March 31, 2021 | -4.03M |
| December 31, 2020 | -3.803M |
| September 30, 2020 | -7.739M |
| June 30, 2020 | -4.016M |
| March 31, 2020 | -2.865M |
| December 31, 2019 | -0.742M |
| September 30, 2019 | -0.626M |
| June 30, 2019 | 16.25M |
| March 31, 2019 | -17.82M |
| December 31, 2018 | -12.42M |
| September 30, 2018 | 0.326M |
| June 30, 2018 | -11.42M |
| March 31, 2018 | -12.93M |
| December 31, 2017 | -9.49M |
| September 30, 2017 | -7.269M |
| June 30, 2017 | -7.409M |
| March 31, 2017 | -7.62M |
| June 30, 2016 | -7.908M |
| March 31, 2016 | -6.108M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| argenx SE | -- |
| ACADIA Pharmaceuticals, Inc. | 95.69M |
| Alnylam Pharmaceuticals, Inc. | 292.04M |
| Anika Therapeutics, Inc. | -2.133M |
| Savara, Inc. | -29.97M |